Lenvatinib plus tislelizumab with or without gefitinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two or three drugs for advanced liver cancer that cannot be removed with surgery. The goal is to see if adding a third drug (gefitinib) to the standard two-drug combination helps patients live longer with better quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed.
- You have not received any prior systemic treatment (like chemotherapy or targeted therapy) for your liver cancer.
- You have at least one measurable tumor that can be tracked by scans.
- You are in generally good health (able to care for yourself) and have adequate liver, kidney, and blood function.
- You are willing to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.